FA
ENGN icon

Fountainhead AM’s enGene Therapeutics ENGN Stock Holding History

Fountainhead AM’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.9K Buy
+15,000
New +$61.2K 0.02% 171

Other funds holding ENGN

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PP
PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Fountainhead AM's ENGN Position: Q2 2026 in Review

Fountainhead AM opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 15,000 shares worth $25.9K. The stake represents 0.02% of the portfolio and ranks #171 among its holdings.

11 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Fountainhead AM held 15,000 shares of enGene Therapeutics worth $25.9K as of Q2 2026.
  • enGene Therapeutics was a new Fountainhead AM position in Q2 2026.
  • enGene Therapeutics made up 0.02% of Fountainhead AM's portfolio in Q2 2026, its #171 holding.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Fountainhead AM's 13F filing for Q2 2026, filed 3 Aug 2026.